Only 6% of eligible patients to receive Mounjaro in first three years, MPs say

The Commons health and social care committee described the NHS rollout of the weight-loss drug as unambitious and warned of a two-tier system.

Only 6% of eligible patients to receive Mounjaro in first three years, MPs say
Photo: The Telegraph

Only around 6 per cent of eligible patients will receive the weight-loss drug Mounjaro in its first three years on the NHS, according to the Commons health and social care committee. The committee said the drug is being rolled out to a "woefully small number of people".

The NHS has given access to 220,000 people over three years. This represents approximately 6 per cent of those eligible based on National Institute for Health and Care Excellence recommendations. The NHS estimated 2.8 million patients would be eligible, and if all presented within the first year, the cost would be £15.2bn over five years.

MPs warned that a "two-tier system" has developed, with millions who can afford to do so turning to private firms, which worsens existing health inequality. Access to GLP-1 medication appears increasingly determined by ability to pay rather than clinical need. More than 2.37 million packs of GLP-1s are prescribed every month in the UK, with the vast majority being accessed privately.

Layla Moran, the Liberal Democrat MP and select committee chairman, said the NHS should provide effective, structured support to beat obesity for all those who seek it. She said weight-loss drugs remain out of reach for those who cannot afford them.

The committee called for the Government to urgently reassess the pace of the Mounjaro rollout. They suggested the department should hold a summit on GLP-1 access with a range of providers and healthcare professionals to improve the rollout.

In a chapter on children, the report noted that in South Yorkshire, around 16,000 children and young people might meet the referral criteria, but there were only enough places to support around 100 families per year. Waiting times for specialised clinics were around six months.

Key facts

  • Only 6 per cent of eligible patients will receive Mounjaro in its first three years on the NHS.
  • The NHS has provided access to 220,000 people over three years.
  • The committee called for obesity to be treated as a long-term, managed condition similar to diabetes.

Three perspectives

Neutral

The NHS is rolling out Mounjaro gradually following an agreement with Nice.

Positive

The committee suggested the Government hold a summit on GLP-1 access to improve the rollout.

Negative

MPs warned that a two-tier system has emerged where access to drugs is determined by the ability to pay.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Next storyUS loses measles elimination status after surge in cases and deaths

All sections

Edition